This brand name is authorized in Austria, Croatia, Ireland, Italy, Lithuania
The drug PEDMARQSI contains one active pharmaceutical ingredient (API):
|
1
Sodium thiosulfate
UNII HX1032V43M - SODIUM THIOSULFATE
|
|
Sodium thiosulfate is indicated for sequential use with sodium nitrite for the treatment of acute cyanide poisoning that is judged to be life-threatening. The primary route of endogenous cyanide detoxification is by enzymatic transulfuration to thiocyanate (SCN-), which is relatively nontoxic and readily excreted in the urine. Sodium thiosulfate is also indicated for the prevention of ototoxicity induced by cisplatin chemotherapy. The mechanism of protection against ototoxicity may include increasing levels of endogenous antioxidants, inhibition of intracellular oxidative stress, and direct interaction between cisplatin and the thiol group in sodium thiosulfate to produce inactive platinum species. |
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| PEDMARQSI Solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: IT | Agenzia del Farmaco | Identifier(s): 050707013 |
| Country: LT | Valstybinฤ vaistลณ kontrolฤs tarnyba | Identifier(s): 1097208 |
ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
